Clinical trial · Observational
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
A Prospective Study for Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Immuno-therapy in Real-world Setting
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Newly Diagnosed Multiple Myeloma (NDMM) | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- newly diagnosed multiple myeloma
Primary outcomes (2)
- measure
- treatment patterns
- timeFrame
- From July 2025 to July 2026
- description
- To describe the treatment patterns of Chinese NDMM patients receiving first-line immunotherapy in real-world settings.
- measure
- real-world overall response rate (rwORR)
- timeFrame
- From July 2025 to July 2026
- description
- To determine the clinical outcomes of Chinese NDMM patients receiving first-line immunotherapy in real-world settings.The real-world overall response rate (rwORR) of the entire population, as well as the rwORR of each treatment regimen.
Secondary outcomes (8)
- measure
- MRD
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed multiple myeloma (NDMM) * Plan to receive first-line immunotherapy at the respective research center * First-line immunotherapy includes proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), or anti-CD38 monoclonal antibodies, used alone or in combination with each other or with other treatments * Age ≥ 18 years * Ability to understand the purpose of the study and follow-up process * Willingness to provide signed and dated written informed consent Exclusion Criteria: \- Patients who did not receive any follow-up after initial diagnosis
References
Publications (0)
Data not yet available